Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

Viking Therapeutics initiated Part 2 of its exploratory VK2735 maintenance study, testing oral and additional subcutaneous regimens in approximately 195 adults with obesity. Participants receive 21 weeks of initial weekly dosing, then transition to maintenance options through Week 33; the study will assess safety, tolerability, pharmacokinetics and exploratory weight changes. Viking expects to report Part 2 results in 2027; positive top-line results from Part 1 were recently announced, but no Part 2 efficacy results are available yet.

Analysis

The incremental value is strategic optionality, not near-term earnings: less-frequent injections or oral maintenance could widen the addressable patient pool and support persistence if efficacy and tolerability hold. But this is a small exploratory study with weight change as an exploratory endpoint, and its 2027 readout leaves the Phase 3 induction program as the primary valuation driver. The company-reported Part 1 result is encouraging but not evidence yet of durable maintenance across routes or dosing intervals.

Second-order competition cuts both ways. Convenient maintenance could help Viking differentiate from established GLP-1 and dual-agonist therapies from Novo Nordisk and Eli Lilly, but those incumbents have scale, marketed products, and room to respond with their own dosing or formulation options. A maintenance regimen that reduces injection frequency could also shift demand away from injectable supply-chain capacity; that benefit accrues only if patients retain weight loss and regulators accept the regimen.

Near term, the announcement is a modest sentiment catalyst, not a basis for repricing commercial prospects. Over 1–3 months, monitor Phase 3 updates and any evidence that the maintenance design translates into a credible clinical advantage. The 6–18 month structural case remains contingent on Phase 3 efficacy/safety and on oral pharmacokinetics, tolerability, and weight retention. The thesis weakens if subsequent data show meaningful regain, poor oral exposure or tolerability, or no differentiation versus available therapies.

Key Decisions for Investors

• Do not chase VKTX solely on this study initiation; treat it as optionality layered onto a Phase 3 clinical-risk story, not a near-term fundamental upgrade.
• For existing VKTX exposure, size around binary clinical catalysts and preserve downside capacity; the next material validation is evidence that weekly induction can be followed by effective, tolerable maintenance, not the existence of multiple study arms.
• Set a watch item for the 2027 Part 2 readout: compare weight change from Week 21, safety/tolerability, and pharmacokinetic exposure across oral and less-frequent injection arms. These details determine whether convenience is a real adherence advantage or merely a dosing claim.
• Reassess the thesis if Phase 3 efficacy or safety disappoints, or if maintenance arms show substantial weight regain or unacceptable tolerability; conversely, robust maintenance data would support a differentiated-product premium, subject to regulatory and commercial validation.